We have an asset which is about to enter IND-enabling studies for pathogens outside this call scope. We have some very positive data in clinical isolates associated with this call scope so we may be able to expand the indication. Would this type of project have a realistic chance of getting funded in this call?

Whilst this call will not fund solely IND enabling studies, carrying out activities within hit-lead and lead optimisation to further validate and align the asset for indications outlined in the call would be in scope. We would therefore encourage you to apply for this call and arrange a meeting with us to discuss in more detail. In your EOI submission, you will need to convey that there is a credible strategy to advance your asset all the way to clinical trials.